Moderna rises on FDA Covid vaccine guidance that doesn't destroy their core business

Moderna's actions (NASDAQ:MRNA) saw an increase of 7% in the afternoon, according to the original report.This growth occurred following the FDA's announcement of new regulatory guidelines for the accelerated approval of COVID vaccines.These guidelines allow faster access to vaccines for older people and for between 100 and 200 million Americans at high risk. Market impact and stock volatilityThe FDA's regulatory adjustment assumes that randomize…

Moderna rises on FDA Covid vaccine guidance that doesn't destroy their core business

While the announcement may hurt Moderna’s sales, FDA officials took a less hostile tone to vaccination broadly....